February 13-14, 1984
Hotel New Otani (Room “Unkai”), Tokyo

The meeting was called to order by Mr. Koichi Igarashi, JSPS Executive Director, at 2:00 p.m. on February 1 3. He solicited the participants’ approval on which he would serve as the chairman, protem, until the co-chairmen would be duly appointed during the process of the meeting.
Mr. Igarashi introduced Dr. Sogo Okamura, Director General, JSPS. Dr. Okamura welcomed the Joint Steering Committee and thanked them for making the long trip across the Pacific Ocean. He stated that the JSPS has appreciated and enjoyed the cooperation during the past ten years. There have been significant and productive contributions toward the advancement of cancer research in both countries through this cooperation. He stated that there has been agreement between the NCI and JSPS to continue the cooperation for another five years, effective from April 1, 1984. Mr. Igarashi believes that the new Comprehensive 10-Year Cancer Control Strategy will add new dimensions and opportunities for expanded cooperation between the U.S. and Japan. The JSPS has been given a slight increase in its budget for FY 1984. The discussions during the morning have provided some ideas as to how the NCI and JSPS can promote cancer research relative to the Comprehensive 10-Year Cancer Control Strategy. This meeting has provided a forum for fruitful discussion. Mr. Igarashi has high hopes for greater progress in the cooperation.
Mr. Igarashi then introduced the members of the JSPS Steering Committee: Dr. Sakai, Executive Director, JSPS; Mr. Katsuya, Head, Program Department, JSPS; Mr. Onozawa. Head, Research Cooperation Division, JSPS; and other members of the JSPS staff (see Appendix II-A).
Dr. Adamson thanked Dr. Okamura for his kind remarks and introduced the NCI delegation: Dr. Schepartz, Deputy Director, Division of Cancer Treatment, NCI; Dr. Robert Miller, Chief, Clinical Epidemiology Branch, Division of Cancer Etiology, NCI; Dr. Richard Hodes, Chief, Immunotherapy Section, Division of Cancer Biology and Diagnosis, NCI; and Dr. Robert Omata, Executive Secretary, U.S.-Japan Cooperative Cancer Research Program.
Mr. Igarashi requested that Dr. Adamson and Dr. Sugimura act as co-chairmen for the remainder of the meeting. The JSPS announced that a reception will be held at 6:00 p.m. Dr. Omata stated that a luncheon at 11:30 a.m. on Tuesday, February 14, will be hosted by Dr. Adamson in honor of Dr. Kitagawa, Mr. Hasegawa, the JSPS Steering Committee, and the JSPS staff.
The co-chairmen called the meeting to order and presented the implementation plan for FY 1984 as formulated by the JSPS (see Appendix II-B). The general plans for FY 1984 are to jointly sponsor ten meetings, five in Japan and five in the U.S., including Hawaii. Tentative plans will provide for two long-term and twelve short-term exchanges; a total of fourteen Japanese exchange scientists to the U.S. and a total of eight American exchange scientists to Japan. The JSPS will provide funds for the production and sending of research materials and reagents for use by American scientists, since the individual scientists in Japan have little or not funds to cover this item. The American scientists have been generous in sharing research materials out of their own budgets.
In addition to the above plans, the JSPS has funds to support two large symposia on a new area of cancer resarch or an area which requires a large number of participants. The JSPS will have funds to invite two senior American guest speakers to Japan and to send as many as ten Japanese scientists to the U.S. for a large symposium. It will be the responsibility of the Joint Steering Committee to decide on the topics for such conferences.
It was pointed out to the JSPS Steering Committee that the FY 1984 and FY 1985 budget for NCI was very tight with little or no surplus to sponsor a large conference in the U.S. under the new format. It may be possible to sponsor such a conference in NCI FY 1985 budget.
Dr. Hodes asked what the JSPS had in mind regarding junior and senior Japanese scientists who wish to study in the U.S., whether the junior scientists would be applying for long-term exchanges and the senior scientists for short-term visits. The JSPS Committee responded that the long-term exchanges would probably be more appropriate for the younger scientists.
Dr. Schepartz stated that cancer drugs sent to Japan were usually from the Division of Cancer Treatment, NCI, and the costs were covered by division funds.
Dr. Sugano then asked that the Joint Committee consider the research interests or areas as listed in Appendix II-C. It was confirmed that the new 5-year continuation program will retain the four program areas; namely, Etiology, Biology and Diagnosis, Treatment and Interdisciplinary. It was recommended that eight research subjects, as listed, be considered by the Joint Committee and assigned to the appropriate Program Areas. These research areas also include the areas which are part of the new 10-Year Cancer Control Strategy.
After some discussion, the Joint Committee agreed to integrate the eight research areas into the existing four Program Areas as follows:

  1. Etiology Program Area
    1. Promotion and inhibition in carcinogenesis
    2. Human tumor virus and viral oncology
    3. Oncogene research
  2. Biology and Diagnosis Program Area
    1. Immunology (basic and preclinical)
    2. Diagnosis
    3. Cell biology
  3. Treatment Program Area
    1. Treatment
    2. Immunology (clinical)
  4. Interdisciplinary Program Area
    1. Epidemiology
    2. Organ site

Dr. Sugimura stated that on the Japanese side; Dr. Yamamura, Dr. Sakurai, Dr. Sugano, and he would continue to serve as Program Area coordinators. Dr. Adamson pointed out that Dr. Hodes, Dr. Miller, and he would continue to serve as Program Area coordinators on the American side. The coordinator for the Treatment Program Area will be named in the near future.
The subject of naming advisors to each research interest was discussed and all of the Program Area coordinators will be prepared to present their slates at the June meeting.
Dr. Sugimura then asked the Committee to present suggestions for the large symposia or conferences.
Dr. Yamamura suggested the following topics: immunology, lymphokines, recombinant DNA, and monoclonal antibodies relative to their chemical and biological significance. Dr. Hodes stated that these topics were very appropriate since there have been considerable advances in those areas. More recently, there has been a closer relationship between molecular biology and immunology as well as that between diagnosis and treatment.
Dr. Adamson stated that recent advances in biological and chemical carcinogenesis have been made through research on promoters and oncogenes and these areas are rapidly developing. Dr. Sugimura concurred that research on promoters and oncogenes would be excellent topics for a large symposium. Dr. Adamson also suggested that cancer epidemiology relative to fat and fiber in the diet would be an interesting topic. Dr. Miller suggested that the relation of food additives and pesticides, such as EDB, would be of great interest. Dr. Sugimura stated that the question of EDB is very important and also the risk estimation of other carcinogens might draw considerable interest. Cancer prevention is another area which is developing a great deal of interest in the U.S. and Japan. He also suggested that a conference on lymphokines might be held in the U.S. while the other conference on oncogenes would be well attended in Japan.
Dr. Sakurai suggested discussions on the effect of chemotherapy on site reduction for host control and new methods of treatment of cancer following chemotherapy using lymphokines or interferon and other biological response modifiers, which can play a large role in the treatment of residual tumor cells. He also suggested clinical studies of combined interferon treatment with chemotherapy.
It was agreed that the following research topics be considered by the Joint Steering Committee to sponsor large symposia during FY 1984: lymphokines, oncogenes, food and cancer, and immunotherapy and chemotherapy.
Dr. Adamson asked the Committee to discuss the activities of the Program Areas for the next year. Dr. Sugimura stated that there have been preliminary discussions for holding workshops or seminars on the following subjects in the Etiology Program Area:

  1. Oncogenes and chemical carcinogenesis. There has been interest in the relationship of nitrosoureas and the inducement of secondary cancers, particularly in the treatment of breast cancer. Drs. Terada and Aaronson were suggested as organizers.
  2. Relationship of monoclonal antibodies to cancer. Dr. Yachi has been interested in this subject.
  3. Mechanism of transformation of DNA tumor viruses. Dr. Reisfeld has been suggested as one of the organizers. He also suggested that the personnel exchanges be in the area of viral oncology and oncogene research.

Dr. Adamson stated that there are two workshops scheduled for February and March 1984, which are related to tumor biology. However, the above three topics would provide interesting subjects for discussion and exchange of information for the next year.
Dr. Hodes reported that two successful meetings were held in October and November 1983 on tumor immunology and oncogene research. He stated that a meeting on immunology and preclinical immunotherapy is being planned for the fall of 1984 in the Biology and Diagnosis Program Area.
Dr. Sakurai reported that three seminars are being planned in the Treatment Program Area for FY 1984. The annual drug review meeting has been discussed and a meeting on radiation oncology, organized by Drs. Abe and Sheline, will be held in Seattle, Washington in May 1984. Another treatment meeting is being planned for October 1984. Dr. Schepartz stated that a drug review meeting will be held in March 1985 to discuss new drugs. He also reported that further collaborative projects are being discussed and planned, which take advantage of the experience gained through the earlier joint cooperative project on treatment of gastric cancer. These potential projects include the evaluation of American drugs in Japan, particularly Phase II drug studies in the treatment of gastirc cancer. In addition, the Program Area coordinators are presently negotiating to have Dr. Tsuruo come to NCI for one year.
Dr. Miller, coordinator for the Interdisciplinary Program Area, reported that a meeting on epidemiologic methods and biostatistics in the studies of cancer will be held in March 1984 in Hiroshima. Dr. David Hoel from NIEHS, who had participated in a previous workshop has been appointed to work at the Radiation Effects Research Foundation (RERF) for two years. On March 10-11, 1984, a workshop on the role of the pathologists in cancer epidemiology will be held in San Francisco, in conjunction with the annual meeting on the International Academy of Pathology. He also discussed two possible meetings for FY 1985 for the program area:

  1. Comparison of data from Japanese tumor tissue registry and the SEER Program in the U.S. There is some interest in the cancer incidence in Japan of people under 30 years of age. This topic is relevant to the areas under the new Comprehensive Cancer Strategy.
  2. Another subject which is related to the Japanese Cancer Control Program is the study of cancer in Southeast Asia. In this regard, a workshop on choriocarcinoma, lymphomas, schistosomiasis and liver cancer, and cancers of the paranasal sinuses would be of considerable interest.

Dr. Miller also mentioned that a substantial number of young Japanese scientists have been invited to work in the U.S. through introductions provided to Americans who participated in workshops held in Japan under the NCI-JSPS Program. This has been an immense extra dividend. Dr. Sugano substantiated this point by reporting that during the past year three Japanese investigators studied in the U.S. as the result of the Workshop on Leukemias and Lymphomas. He also reported that a Japanese scientist will be going to study in California as a result of the Workshop on Liver Cancer. The visits of three American scientists to Japan were highly successful and productive. Dr. Adamson reiterated that studies on hepatitis virus in Southeast Asia are of considerably interest and the latest information on human T-cell leukemia virus (HTLV) and adult T-cell leukemia virus (ATLV) continues to be of great mutual interest. The relationship of EBV to nasopharyngeal cancer is also of interest in view of the recent migration of Southeast Asians to the U.S.
The dates for the next Joint Steering Committee were discussed. It was decided that the meeting will be held on June 25-26, 1984, in San Francisco, California.
Mr. Igarashi thanked the Joint Steering Committee members for attending this meeting and the discussions were most useful and worthwhile. The meeting was adjourned by Dr. Adamson at 4:30 p.m.

Respectfully submitted,

Dr. Robert R. Omata


February 13-14, 1984
Hotel New Otani (Room “Unkai”), Tokyo


Dr. Richard A. Adamson
Director, Division of Cancer Etiology
National Cancer Institute

Dr. Richard J. Hodes
Chief, Immunotherapy Section
Immunology Branch
Division of Cancer Biology and Diagnosis
National Cancer Institute

Dr. Robert W. Miller
Chief, Clinical Epidemiology Branch
Division of Cancer Cause and Prevention
National Cancer Institute

Dr. Saul A. Schepartz
Deputy Director
Division of Cancer Treatment
National Cancer Institute

Dr. Robert R. Omata
Executive Secretary
US-Japan Cooperative Cancer Research Program
Office of International Affairs
National Cancer Institute

JSPS Program Coordinators

Dr. Takashi Sugimura
Director, National Cancer Center
Research Institute

Dr. Yuichi Yamamura
President, Osaka University

Dr. Yoshio Sakurai
Director, Cancer Chemotherapy Center
Japanese Foundation for Cancer Research

Dr. Haruo Sugano
Director, Cancer Institute
Japanese Foundation for Cancer Research

JSPS Representatives

Dr. Sogo Okamura
Director General

Mr. Koichi Igarashi
Executive Director

Dr. Fuminori Sakai
Executive Director

Mr. Yuichi Katsuya
Head, Program Department

Mr. Nagahide Onozawa
Head, Research Cooperation Division



Research interest:
1. Promotion and inhibition in carcinogenesis
2. Human tumor virus and viral oncology
3. Oncogene
4. Cell biology
5. Immunology
6. Diagnosis
7. Treatment
8. Epidemiology and organ site